Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681
Recruiting
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5 mg/kg) every 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: INOVA Schar Cancer Institute, Fairfax, Virginia
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
NCT04996173
Recruiting
Benign central airway stenosis (BCAS) is an important cause of both pulmonary morbidity and mortality. Notable causes include post-intubation stenosis, collagen vascular diseases, airway trauma, infectious and idiopathic subglottic stenosis (iSGS). Surgery is the preferred definite option; however, the first therapeutic attempt is usually endoscopic to temporarily restore airway patency and symptomatic improvement. Several endoscopic modalities exist for treatment. Most commonly, thermal or las... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Pulmonary Disease
Register for Updates
Down Syndrome Obstructive Sleep Apnea
NCT06043440
Recruiting
The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
04/18/2025
Locations: East Virginia Medical Center, Norfolk, Virginia
Conditions: Down Syndrome, Obstructive Sleep Apnea
Register for Updates
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
NCT05727878
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, Norfolk, Virginia
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT06248606
Recruiting
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Non Small Cell Lung Cancer, NSCLC, KRAS G12C
Register for Updates
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
NCT05653518
Recruiting
This study will examine the potential cardiovascular effect(s) of artificial pancreas (AP) technology in patients with type 1 diabetes. AP technology is a system of devices that closely mimics the glucose-regulating function of a healthy human pancreas. It includes an insulin pump and a continuous glucose monitor (CGM). In this study, the investigators will research whether improvements in blood glucose levels and blood glucose variability will in turn decrease biomarkers of inflammation and end... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/17/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Type 1 Diabetes
Register for Updates
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
Register for Updates
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
NCT03458832
Recruiting
The primary cause of facioscapulohumeral muscular dystrophy (FSHD), a common adult-onset dystrophy, was recently discovered identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures (FSHD-COM and EIM) and optimize eligibility crit... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Facioscapulohumeral Muscular Dystrophy
Register for Updates
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628
Recruiting
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Richmond, Virginia
Conditions: Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
Register for Updates
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
NCT06029660
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Inova Schar Heart and Vascular, Falls Church, Virginia
Conditions: Aortic Aneurysm, Abdominal
Register for Updates
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT04315233
Recruiting
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Register for Updates